Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy

NCT04229979 is registered in ClinicalTrials.gov with Sellas Life Sciences Group as lead sponsor.

NCT NCT04229979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects With Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
Lead sponsor
Sellas Life Sciences Group
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 8, 2021
Completion date
December 31, 2026
Enrollment
127 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia